Effect of ximenynic acid on cell cycle arrest and apoptosis and COX-1 in HepG2 cells

Cai,Fang; Li,Jianying; Liu,Yandi; Zhang,Zunyi; Hettiarachchi,D.   S.; Li,Duo

doi:10.3892/mmr.2016.5920

Effect of ximenynic acid on cell cycle arrest and apoptosis and COX-1 in HepG2 cells

Authors:
- Fang Cai
- Jianying Li
- Yandi Liu
- Zunyi Zhang
- D. S. Hettiarachchi
- Duo Li
View Affiliations

Affiliations: Department of Food Science and Nutrition, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China, Institute of Developmental and Regenerative Biology, Hangzhou Normal University, Hangzhou, Zhejiang 310000, P.R. China, School of Pharmacy, Curtin Health Innovation Research Institute, Curtin University, Perth 02042G, Australia
Published online on: November 3, 2016 https://doi.org/10.3892/mmr.2016.5920
Pages: 5667-5676

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ximenynic acid is a conjugated enyne fatty acid, which is currently of interest due to its anti-inflammatory activity. Due to the association between inflammation and cancer, the present study was designed to investigate the anti‑cancer activity of ximenynic acid in the HepG2 human hepatoma cell line and the underlying mechanisms. The current study demonstrated the anti‑proliferation and pro‑apoptosis activities of ximenynic acid by cell viability assay and flow cytometry analysis. The expression of anti‑apoptosis protein silent information regulator T1 (SIRT1) was significantly suppressed by ximenynic acid. Furthermore, ximenynic acid blocked G1/S phase transition by inhibiting the protein expression of the cell cycle‑associated protein general control of amino acid synthesis yeast homolog like 2 (GCN5L2), and the mRNA expression of cyclin D3 and cyclin E1. Furthermore, ximenynic acid suppressed the expression of angiogenesis‑associated genes, including vascular endothelial growth factor (VEGF)‑B and VEGF‑C. Finally, ximenynic acid significantly inhibited the expression of cyclooxygenase‑1 (COX‑1) mRNA and protein, however COX‑2 expression was not reduced. The results of the present study suggested that ximenynic acid may inhibit growth of HepG2 cells by selective inhibition of COX‑1 expression, which leads to cell cycle arrest, and alters the apoptosis pathway and expression of angiogenic factors. The current study aimed to investigate whether ximenynic acid might be developed as novel anticancer agent.

View Figures

View References

1	Aitzetmuller K: Santalbic acid in the plant kingdom. Plant Syst Evol. 298:1609–1617. 2012. View Article : Google Scholar
2	Shawar RM, Humble DJ, Van Dalfsen JM, Stover CK, Hickey MJ, Steele S, Mitscher LA and Baker W: Rapid screening of natural products for antimycobacterial activity by using luciferase-expressing strains of Mycobacterium bovis BCG and Mycobacterium intracellulare. Antimicrob Agents Chemother. 41:570–574. 1997.PubMed/NCBI
3	Jones GP, Rao KS, Tucker DJ, Richardson B, Barnes A and Rivett DE: Antimicrobial activity of santalbic acid from the oil of Santalum-Acuminatum (Quandong). Int J Pharmacogn. 33:120–123. 1995. View Article : Google Scholar
4	Croft KD, Beilin LJ and Ford GL: Differential inhibition of thromboxane B2 and leukotriene B4 biosynthesis by two naturally occurring acetylenic fatty acids. Biochim Biophys Acta. 921:621–624. 1987. View Article : Google Scholar : PubMed/NCBI
5	Nugteren DH and Christ-Hazelhof E: Naturally occurring conjugated octadecatrienoic acids are strong inhibitors of prostaglandin biosynthesis. Prostaglandins. 33:403–417. 1987. View Article : Google Scholar : PubMed/NCBI
6	Li G, Singh A, Liu Y, Sunderland B and Li D: Comparative effects of sandalwood seed oil on fatty acid profiles and inflammatory factors in rats. Lipids. 48:105–113. 2013. View Article : Google Scholar : PubMed/NCBI
7	Imig JD and Hammock BD: Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 8:794–805. 2009. View Article : Google Scholar : PubMed/NCBI
8	Wang D and Dubois RN: Eicosanoids and cancer. Nat Rev Cancer. 10:181–193. 2010. View Article : Google Scholar : PubMed/NCBI
9	Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z and Meade TW: Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 379:1602–1612. 2012. View Article : Google Scholar : PubMed/NCBI
10	Dembitsky V: Anticancer activity of natural and synthetic acetylenic lipids. Lipids. 41:883–924. 2006. View Article : Google Scholar : PubMed/NCBI
11	Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK and DuBois RN: Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 63:906–911. 2003.PubMed/NCBI
12	Cho M, Kabir SM, Dong Y, Lee E, Rice VM, Khabele D and Son DS: Aspirin blocks EGF-stimulated cell viability in a COX-1 dependent manner in ovarian cancer cells. J Cancer. 4:671–678. 2013. View Article : Google Scholar : PubMed/NCBI
13	Wu WK, Sung JJ, Wu YC, Li HT, Yu L, Li ZJ and Cho CH: Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells. Biochem Biophys Res Commun. 382:79–84. 2009. View Article : Google Scholar : PubMed/NCBI
14	Sano H, Noguchi T, Miyajima A, Hashimoto Y and Miyachi H: Anti-angiogenic activity of basic-type, selective cyclooxygenase (COX)-1 inhibitors. Bioorg Med Chem Lett. 16:3068–3072. 2006. View Article : Google Scholar : PubMed/NCBI
15	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
16	Schwartz GK and Shah MA: Targeting the cell cycle: A new approach to cancer therapy. J Clin Oncol. 23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
17	Liu YD, Longmore RB and Fox JED: Separation and identification of ximenynic acid isomers in the seed oil of Santalum spicatum RBr as their 4,4-dimethyloxazoline derivatives. J Am Oil Chem Soc. 73:1729–1731. 1996. View Article : Google Scholar
18	Sun G, Zhou Y, Li H, Guo Y, Shan J, Xia M, Li Y, Li S, Long D and Feng L: Over-expression of microRNA-494 up-regulates hypoxia-inducible factor-1 alpha expression via PI3K/Akt pathway and protects against hypoxia-induced apoptosis. J Biomed Sci. 20:1002013. View Article : Google Scholar : PubMed/NCBI
19	Herrmann E, Call J, Hernandez-Lloreda MV, Hare B and Tomasello M: Humans have evolved specialized skills of social cognition: The cultural intelligence hypothesis. Science. 317:1360–1366. 2007. View Article : Google Scholar : PubMed/NCBI
20	Han Z, Hendrickson EA, Bremner TA and Wyche JH: A sequential two-step mechanism for the production of the mature p17:p12 form of caspase-3 in vitro. J Biol Chem. 272:13432–13436. 1997. View Article : Google Scholar : PubMed/NCBI
21	Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L and Weinberg RA: hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107:149–159. 2001. View Article : Google Scholar : PubMed/NCBI
22	Ford J, Jiang M and Milner J: Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 65:10457–10463. 2005. View Article : Google Scholar : PubMed/NCBI
23	Kikuchi H, Takami Y and Nakayama T: GCN5: A supervisor in all-inclusive control of vertebrate cell cycle progression through transcription regulation of various cell cycle-related genes. Gene. 347:83–97. 2005. View Article : Google Scholar : PubMed/NCBI
24	Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
25	Regan JW: EP2 and EP4 prostanoid receptor signaling. Life Sci. 74:143–153. 2003. View Article : Google Scholar : PubMed/NCBI
26	Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J. 13:9–22. 1999.PubMed/NCBI
27	Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ and Murphy WJ: Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression. Blood. 96:34–40. 2000.PubMed/NCBI
28	Volp K, Brezniceanu ML, Bösser S, Brabletz T, Kirchner T, Göttel D, Joos S and Zörnig M: Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 55:234–242. 2006. View Article : Google Scholar : PubMed/NCBI
29	Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:485–490. 1998. View Article : Google Scholar : PubMed/NCBI
30	Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Böttinger EP, Chen Y, Zhu HJ, Kang DH, Schreiner GF, et al: TGF-beta induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. Kidney Int. 66:605–613. 2004. View Article : Google Scholar : PubMed/NCBI
31	Grana X and Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
32	Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582. 1994. View Article : Google Scholar : PubMed/NCBI
33	Fimognari C, Nüsse M, Berti F, Iori R, Cantelli-Forti G and Hrelia P: Cyclin D3 and p53 mediate sulforaphane-induced cell cycle delay and apoptosis in non-transformed human T lymphocytes. Cell Mol Life Sci. 59:2004–2012. 2002. View Article : Google Scholar : PubMed/NCBI
34	Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, et al: Cyclin E and survival in patients with breast cancer. N Engl J Med. 347:1566–1575. 2002. View Article : Google Scholar : PubMed/NCBI
35	Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM and Pagano M: Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol. 15:2612–2624. 1995. View Article : Google Scholar : PubMed/NCBI
36	Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y, Deng A, Chen J, Wang G, Zhu S and Kang J: Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression. J Biol Chem. 288:14510–14521. 2013. View Article : Google Scholar : PubMed/NCBI
37	Longo VD and Kennedy BK: Sirtuins in aging and age-related disease. Cell. 126:257–268. 2006. View Article : Google Scholar : PubMed/NCBI
38	Liu T, Liu PY and Marshall GM: The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 69:1702–1705. 2009. View Article : Google Scholar : PubMed/NCBI
39	Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI
40	Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 30:3–21. 2000.PubMed/NCBI
41	Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN and Dey SK: Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 65:3735–3744. 2005. View Article : Google Scholar : PubMed/NCBI
42	Wu Q, Wang H, Zhao X, Shi Y, Jin M, Wan B, Xu H, Cheng Y, Ge H and Zhang Y: Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma. Oncogene. 32:5541–5550. 2013. View Article : Google Scholar : PubMed/NCBI
43	Yang DH, Hsu CF, Lin CY, Guo JY, Yu WC and Chang VH: Kruppel-like factor 10 upregulates the expression of cyclooxygenase 1 and further modulates angiogenesis in endothelial cell and platelet aggregation in gene-deficient mice. Int J Biochem Cell Biol. 45:419–428. 2013. View Article : Google Scholar : PubMed/NCBI
44	Pittet JF, Koh H, Fang X, Iles K, Christiaans S, Anjun N, Wagener BM, Park DW, Zmijewski JW, Matthay MA and Roux J: HMGB1 accelerates alveolar epithelial repair via an IL-1β- and αvβ6 integrin-dependent activation of TGF-β1. PloS One. 8:e639072013. View Article : Google Scholar : PubMed/NCBI
45	Kim HY, Park SY, Lee SW, Lee HR, Lee WS, Rhim BY, Hong KW and Kim CD: Inhibition of HMGB1-induced angiogenesis by cilostazol via SIRT1 activation in synovial fibroblasts from rheumatoid arthritis. PloS One. 9:e1047432014. View Article : Google Scholar : PubMed/NCBI
46	Taniura S, Kamitani H, Watanabe T and Eling TE: Transcriptional regulation of cyclooxygenase-1 by histone deacetylase inhibitors in normal human astrocyte cells. J Biol Chem. 277:16823–16830. 2002. View Article : Google Scholar : PubMed/NCBI
47	Omura N, Griffith M, Vincent A, Li A, Hong SM, Walter K, Borges M and Goggins M: Cyclooxygenase-deficient pancreatic cancer cells utilize exogenous sources of prostaglandins. Mol Cancer Res. 8:821–832. 2010. View Article : Google Scholar : PubMed/NCBI
48	Kolaczkowska E, Koziol A, Plytycz B, Arnold B and Opdenakker G: Altered apoptosis of inflammatory neutrophils in MMP-9-deficient mice is due to lower expression and activity of caspase-3. Immunol Lett. 126:73–82. 2009. View Article : Google Scholar : PubMed/NCBI
49	Son DS, Wilson AJ, Parl AK and Khabele D: The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biol Ther. 9:928–935. 2010. View Article : Google Scholar : PubMed/NCBI